PTG fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
PolTREG SA develops and commercializes patented TREG methods. It engages in the research, development, implementation, and commercialization of T-regulatory lymphocytes and using their growth method for clinical use to treat type 1 diabetes. The company was founded in 2015 by Piotr Trzonkowski, Malgorzata Mysliwiec, Wojciech Tadeusz Kakol and Natalia Maria Marek Trzonkowska and is headquartered in Gdansk, Poland.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
PTG has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company